SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Panacea Biotec’s arm launches Paclitaxel Protein-Bound Particles for Injectable Suspension

28 Oct 2023 Evaluate

Panacea Biotec’s material wholly owned subsidiary -- Panacea Biotec Pharma through its strategic partner Apotex Inc., Canada has launched Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound), a generic version of Abraxane in the Canadian market.

Paclitaxel Protein-Bound Particles for Injectable Suspension is indicated for the treatment of metastatic breast cancer, non-small cell lung cancer and adenocarcinoma of the pancreas. ABRAXANE is a registered trademark of Abraxis BioScience, LLC, which is a wholly owned subsidiary of Bristol- Myers Squibb Company. This is the first generic launch of Abraxane in Canada and provides patients with a high quality medication at an affordable price. The current market size of Abraxane in Canada is $26.4 million.

Panacea Biotec had an existing collaboration agreement with Apotex Inc. for research, development, license, supply and sale of the said Product in US, Canada, Australia & New Zealand. Pursuant to the said collaboration agreement Panacea Biotec had undertaken research, development and manufacturing of the product at its stateof-the art pharmaceutical formulations facility at Baddi, Himachal Pradesh and Apotex Inc. will undertake the marketing, sales and distribution thereof in the Canadian market.

Panacea Biotec is a leading research based Biotechnology Company with established research, manufacturing and marketing capabilities.


Panacea Biotec Share Price

537.30 11.70 (2.23%)
12-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1807.25
Dr. Reddys Lab 1273.90
Cipla 1388.80
Zydus Lifesciences 1104.35
Lupin 2292.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: